Literature DB >> 26522003

Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.

A M Garcia Vicente1, A Soriano Castrejón2, M Amo-Salas3, J F Lopez Fidalgo3, M M Muñoz Sanchez4, R Alvarez Cabellos5, R Espinosa Aunion6, V Muñoz Madero7.   

Abstract

AIM: To explore the relationship between basal (18)F-FDG uptake in breast tumors and survival in patients with breast cancer (BC) using a molecular phenotype approach.
MATERIAL AND METHODS: This prospective and multicentre study included 193 women diagnosed with BC. All patients underwent an (18)F-FDG PET/CT prior to treatment. Maximum standardized uptake value (SUVmax) in tumor (T), lymph nodes (N), and the N/T index was obtained in all the cases. Metabolic stage was established. As regards biological prognostic parameters, tumors were classified into molecular sub-types and risk categories. Overall survival (OS) and disease free survival (DFS) were obtained. An analysis was performed on the relationship between semi-quantitative metabolic parameters with molecular phenotypes and risk categories. The effect of molecular sub-type and risk categories in prognosis was analyzed using Kaplan-Meier and univariate and multivariate tests.
RESULTS: Statistical differences were found in both SUVT and SUVN, according to the molecular sub-types and risk classifications, with higher semi-quantitative values in more biologically aggressive tumors. No statistical differences were observed with respect to the N/T index. Kaplan-Meier analysis revealed that risk categories were significantly related to DFS and OS. In the multivariate analysis, metabolic stage and risk phenotype showed a significant association with DFS.
CONCLUSION: High-risk phenotype category showed a worst prognosis with respect to the other categories with higher SUVmax in primary tumor and lymph nodes.
Copyright © 2015 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG PET/CT; (18)F-FDG PET/TC; Breast cancer; Cáncer de mama; Disease free status; Disease free survival; Estado libre de enfermedad; Fenotipos moleculares; Molecular phenotypes; Overall survival; Prognosis; Pronóstico; Supervivencia global; Supervivencia libre de enfermedad

Mesh:

Substances:

Year:  2015        PMID: 26522003     DOI: 10.1016/j.remn.2015.08.001

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  4 in total

1.  PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.

Authors:  Lidija Antunovic; Rita De Sanctis; Luca Cozzi; Margarita Kirienko; Andrea Sagona; Rosalba Torrisi; Corrado Tinterri; Armando Santoro; Arturo Chiti; Renata Zelic; Martina Sollini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-26       Impact factor: 9.236

2.  Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.

Authors:  Marianna Sirico; Ottavia Bernocchi; Navid Sobhani; Fabiola Giudici; Silvia P Corona; Claudio Vernieri; Federico Nichetti; Maria Rosa Cappelletti; Manuela Milani; Carla Strina; Valeria Cervoni; Giuseppina Barbieri; Nicoletta Ziglioli; Martina Dester; Giulia Valeria Bianchi; Filippo De Braud; Daniele Generali
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

Review 3.  Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer.

Authors:  J Orcajo-Rincon; J Muñoz-Langa; J M Sepúlveda-Sánchez; G C Fernández-Pérez; M Martínez; E Noriega-Álvarez; S Sanz-Viedma; J C Vilanova; A Luna
Journal:  Clin Transl Oncol       Date:  2022-02-13       Impact factor: 3.340

4.  Developing a personalized treatment model based on molecular biomarkers and imaging in breast cancer: Has the time come?

Authors:  Partha Choudhury
Journal:  Indian J Nucl Med       Date:  2016 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.